[1]宋传伟,刘兆芳,刘兆琳.血清Tg、TgAb、ZEB1水平对甲状腺癌术后清甲治疗患者疾病复发的预测价值[J].陕西医学杂志,2025,54(6):825-829,851.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.020]
　SONG Chuanwei,LIU Zhaofang,LIU Zhaolin.Predictive value of Tg,TgAb and ZEB1 levels for recurrence of thyroid cancer in patients with thyroid remnant ablation after thyroidectomy[J].,2025,54(6):825-829,851.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.020]
点击复制

血清Tg、TgAb、ZEB1水平对甲状腺癌术后清甲治疗患者疾病复发的预测价值

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年6期
页码:
825-829,851
栏目:
临床检验
出版日期:
2025-06-05

文章信息/Info

Title:
Predictive value of Tg,TgAb and ZEB1 levels for recurrence of thyroid cancer in patients with thyroid remnant ablation after thyroidectomy
作者:
宋传伟1; 刘兆芳2; 刘兆琳3
（1.菏泽市立医院乳甲外科，山东 菏泽 274000；2.菏泽市立医院耳鼻咽喉头颈外科，山东 菏泽 274000；3.菏泽市立医院病理科，山东 菏泽 274000）
Author(s):
SONG Chuanwei1; LIU Zhaofang2; LIU Zhaolin3
(1.Department of Breast and Thyroid Surgery,Heze Municipal Hospital,Heze 274000,China;2.Department of Otorhinolaryngology Head and Neck Surgery,Heze Municipal Hospital,Heze 274000,China;3.Department of Pathology,Heze Municipal Hospital,Heze 274000,China)
关键词:
甲状腺癌; 甲状腺球蛋白; 甲状腺球蛋白抗体; E盒结合锌指蛋白1; 复发; 预测价值
Keywords:
Thyroid cancer; Thyroglobulin; Thyroglobulin antibody; Zinc finger E-box binding protein 1; Recurrence; Predictive value
分类号:
R 736.1
DOI:
DOI:10.3969/j.issn.1000-7377.2025.06.020
文献标志码:
A
摘要:
目的：探讨血清甲状腺球蛋白（Tg）、甲状腺球蛋白抗体（TgAb）及E盒结合锌指蛋白1（ZEB1）水平对甲状腺癌术后清甲治疗患者疾病复发的预测价值。方法：选取实施甲状腺手术且术后接受清甲治疗随访5年出现复发的患者48例为复发组，选取年龄、性别基本匹配的同期术后清甲治疗且未发生复发的患者102例为对照组。比较两组患者清甲治疗后12个月Tg、TgAb、ZEB1 mRNA水平以及病理特征、131I治疗情况，分析甲状腺癌术后清甲治疗患者疾病复发影响因素以及Tg、TgAb、ZEB1 mRNA水平对患者术后复发的预测价值。结果：复发组Tg、TgAb、ZEB1 mRNA水平高于对照组患者（均P<0.05）。复发组滤泡状癌、TNM分期Ⅲ-Ⅳ期、次全切手术、肿瘤直径≥5.0 cm、淋巴结转移、血管浸润、手术切缘阳性、24 h 131I摄取率<10%占比高于对照组（均P<0.05）。高Tg、高TgAb、高ZEB1 mRNA、滤泡状癌、TNM分期Ⅲ-Ⅳ期、手术次全切、淋巴结转移、24 h 131I摄取率<10%是甲状腺癌术后清甲治疗患者疾病复发的危险因素（均P<0.05）。Tg、TgAb、ZEB1 mRNA及三项联合预测甲状腺癌术后清甲治疗患者疾病复发的曲线下面积（AUC）分别为0.747、0.787、0.869、0.884。结论：血清Tg、TgAb、ZEB1 mRNA水平与甲状腺癌术后清甲治疗患者疾病复发关系密切，且三项联合对复发具有较高的预测价值。
Abstract:
Objective:To investigate the predictive value of serum thyroglobulin (Tg),thyroglobulin antibody (TgAb) and zinc finger E-box binding protein 1 (ZEB1) levels for recurrence of thyroid cancer in patients with thyroid remnant ablation after thyroidectomy.Methods：A total of 48 patients who underwent thyroid surgery and thyroid remnant ablation and followed up for 5 years and had recurrence were selected as the recurrence group.A total of 102 age- and gender-matched patients who received thyroid remnant ablation and had no recurrence during the same period were enrolled as the control group.The levels of Tg,TgAb and ZEB1 mRNA,pathological characteristics and 131I treatment were compared between the two groups 12 months after thyroid remnant ablation.The influencing factors of disease recurrence in patients with thyroid cancer after thyroid remnant ablation and the predictive value of Tg,TgAb and ZEB1 mRNA levels for postoperative recurrence were analyzed.Results:The levels of Tg,TgAb and ZEB1 mRNA in the recurrence group were higher than those in the control group (all P<0.05).The proportions of follicular carcinoma,TNM stage Ⅲ-Ⅳ,subtotal resection,tumor diameter ≥5.0 cm,lymph node metastasis,vascular invasion,positive surgical margin,and 24-hour 131I uptake rate <10% in the recurrence group were higher than those in the control group (all P<0.05).High Tg,high TgAb,high ZEB1 mRNA,follicular carcinoma,TNM stage Ⅲ-Ⅳ,subtotal resection,lymph node metastasis,24-hour 131I uptake rate <10% were risk factors for recurrence in patients with thyroid cancer after thyroid remnant ablation (all P<0.05).The AUC of Tg,TgAb,ZEB1 mRNA and their combination in predicting recurrence of thyroid cancer patients treated with postoperative thyroid remnant ablation were 0.747,0.787,0.869 and 0.884,respectively.Conclusion:The levels of serum Tg,TgAb and ZEB1 mRNA are closely related to the recurrence of thyroid cancer patients after thyroid remnant ablation,and the combination of the three has a high predictive value for recurrence.

参考文献/References:

[1]傅强,黄学阳,王建春,等.养阴散结汤辅助治疗分化型甲状腺癌疗效及对患者术后甲状腺、免疫功能和血清学指标的影响[J].陕西中医,2022,43(8)：1029-1031,1036.
[2]赵莉娅,赵铁铮,庞英,等.乐伐替尼对甲状腺癌SW579细胞放射敏感性及血管内皮生长因子、碱性成纤维细胞生长因子、碱性成纤维细胞生长因子受体表达的影响[J].陕西医学杂志,2023,52(8)：956-959,968.
[3]潘林宏,李林,黄鹏.血清Tg、TgAb及TSH监测在分化型甲状腺癌131I治疗随访中的意义[J].分子诊断与治疗杂志,2023,15(10)：1816-1819.
[4]HUANG D,ZHI J,ZHANG J,et al.Relationship between thyroid autoantibodies and recurrence of papillary thyroid carcinoma in children and adolescents[J].Front Oncol,2022,12：883591.
[5]LI X,LI H,YAN Y,et al.Metastatic differentiated thyroid cancer with negative serum stimulated Tg but positive post-therapeutic 131I-SPECT/CT scintigraphy：A single-center retrospective study[J].Endocrine,2023,82(1)：117-125.
[6]申伟,张霖雷,严丽,等.微小RNA-204抑制E盒结合锌指蛋白1调控上皮-间充质转化途径影响甲状腺癌细胞侵袭能力的机制[J].中华实验外科杂志,2021,38(4)：645-647.
[7]李小毅.2015年美国甲状腺学会《成人甲状腺结节与分化型甲状腺癌诊治指南》解读：外科部分[J].中国癌症杂志,2016,26(1)：13-18.
[8]高长俊,张晴,韩静.免疫性血小板减少症患儿T淋巴细胞亚群、甲状腺自身抗体、微小RNA-106b-5p和微小RNA-181a-5p表达水平检测及临床意义[J].陕西医学杂志,2023,52(6)：741-744,749.
[9]李旭枝,安小莉,董雯,等.平消胶囊辅助治疗分化型甲状腺癌术后131I放疗患者的临床观察[J].陕西中医,2016,37(4)：456-458.
[10]王树庚.健脾益气汤联合化疗治疗甲状腺癌及对患者免疫功能的影响[J].陕西中医,2016,37(10)：1372-1373.
[11]俞杨,姚嘉,杨时平,等.miR-32-5p靶向ZEB1、ZEB2基因调控乳腺癌增殖和侵袭能力的机制[J].临床与实验病理学杂志,2021,37(3)：264-270.
[12]杨斌峰,王斌.ZEB1干扰通过激发线粒体途径诱导非小细胞肺癌A549细胞凋亡[J].肿瘤药学,2020,10(1)：46-52.
[13]杨小云,陈燕萍,胡益冰,等.血清PDCD4、ZEB1、G-17联合检测对早期胃癌的诊断价值[J].局解手术学杂志,2023,32(4)：323-327.
[14]柳家荣,张琪.ZEB1基因在甲状腺乳头状癌诊断中的意义及对细胞上皮-间质转化的影响[J].实用癌症杂志,2022,37(8)：1224-1228.
[15]钟淙,石琴,章超.lncRNA MALAT1调控miR-144-3p/ZEB1对肺癌放射敏感性的影响[J].实用肿瘤杂志,2022,37(4)：307-314.
[16]张道宝,徐建国.miR-200家族及侵袭相关基因ZEB1、ZEB2和CTNNB1在颅咽管瘤组织中的表达及意义[J].临床神经外科杂志,2022,19(2)：167-170.
[17]黄丽群,谢龙,张冠杰,等.白藜芦醇下调E盒结合锌指蛋白1表达对甲状腺癌细胞侵袭、迁移的影响[J].中国临床药理学杂志,2021,37(15)：2035-2038.
[18]仲亚东,孔德桐,马伯敏.甲状腺癌患者组织及手术前后血清中NR3C2和ZEB1表达水平及其与预后价值研究[J].现代检验医学杂志,2023,38(4)：94-99.
[19]CAMPENN A,RUGGERI R M,SIRACUSA M,et al.Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients[J].Eur J Nucl Med Mol Imaging,2021,48(8)：2466-2475.
[20]白鑫,武新宇,张洁,等.血清TgAb阳性甲状腺乳头状癌患者首次131I治疗的疗效及影响因素分析 [J].中华核医学与分子影像杂志,2024,44(8)：468-472.
[21]谢磊,柴凡,鲍刚,等.血清Tg、TgAb对甲状腺癌根治术联合131I治疗后随访期间复发/转移的评估价值[J].中国现代医学杂志,2023,33(19)：74-79.
[22]张雪鹤.甲状腺超声联合血清Tg、TgAb对甲状腺癌术后复发诊断中的作用[J].河北医科大学学报,2022,43(4)：455-459,465.
[23]杨元芳,赵焕,郝莉.分化型甲状腺癌患者术后复发转移的临床指标及相关影响因素分析[J].实用癌症杂志,2022,37(10)：1619-1621,1631.
[24]纪玲霞,周爱琴,周雪梅.调强放疗治疗甲状腺癌术后残留和复发的临床效果研究[J].实用癌症杂志,2022,37(5)：858-860.
[25]徐振华,易峰涛,黄颖.鼻咽癌根治性放疗后出现单个器官寡转移后手术干预治疗的疗效观察[J].实用肿瘤杂志,2020,35(2)：185-186.

相似文献/References:

[1]陈宏月,李兴江△.甲状腺全切除术对甲状腺癌患者血清血管内皮生长因子、可溶性Fas受体、可溶性Fas受体配体mRNA表达的影响研究[J].陕西医学杂志,2020,49(1):96.
　CHEN Hongyue,LI Xingjiang..Effect of total thyroidectomy on mRNA expression levels of VEGF,sFas and sFasL in serum of patients with thyroid cancer[J].,2020,49(6):96.
[2]谢新静,李忠原.实时剪切波弹性成像联合甲状腺球蛋白抗体检测在甲状腺癌诊断中的应用研究[J].陕西医学杂志,2021,50(2):154.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.007]
　XIE Xinjing,LI Zhongyuan.Application of real-time shear wave elastography combined with Tg-Ab detection in diagnosis of thyroid cancer[J].,2021,50(6):154.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.007]
[3]林松荣,张 磊,罗金现,等.DNA甲基化修饰在甲状腺癌中的研究进展[J].陕西医学杂志,2021,50(2):254.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.033]
　LIN Songrong,ZHANG Lei,LUO Jinxian,et al.Research progress of DNA methylation in thyroid cancer[J].,2021,50(6):254.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.033]
[4]石维超,张少波.甲状腺癌病理微血管密度与颈部淋巴结转移相关性研究[J].陕西医学杂志,2022,51(11):1449.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.031]
　SHI Weichao,ZHANG Shaobo.Correlation between pathological microvessel density and cervical lymph node metastasis in thyroid cancer[J].,2022,51(6):1449.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.031]
[5]王媛媛,朱 静,刘娜娜,等.溶质载体家族1成员5及谷氨酰胺酶2对人甲状腺癌细胞体外恶性行为的影响及机制研究[J].陕西医学杂志,2023,52(3):344.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.023]
　WANG Yuanyuan,ZHU Jing,LIU Nana,et al.Effect of solute carrier family 1 member 5 and glutaminases 2 on malignant behavior of human thyroid cancer cells in vitro and its mechanism[J].,2023,52(6):344.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.023]
[6]华春波,陶宣辰,吕家誉,等.甲状腺癌组织miR-338、miR-143表达及其与患者临床病理特征和预后的关系[J].陕西医学杂志,2025,54(6):830.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.021]
　HUA Chunbo,TAO Xuanchen,LYU Jiayu,et al.Expression of miR-338 and miR-143 in thyroid cancer tissues and their relationship with clinicopathologic features and prognosis[J].,2025,54(6):830.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.021]

备注/Memo

备注/Memo:
山东省医药卫生科技项目(202303121312)
更新日期/Last Update: 2025-06-04